Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NAUT 
Nautilus Biotechnology Inc (NAUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: NAUT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.13% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 190.72M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 4 | Beta 1.46 | 52 Weeks Range 0.62 - 2.67 | Updated Date 11/7/2025 |
52 Weeks Range 0.62 - 2.67 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date 2025-10-28 | When - | Estimate -0.15 | Actual -0.11 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.37% | Return on Equity (TTM) -32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -9918219 | Price to Sales(TTM) - |
Enterprise Value -9918219 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2 | Shares Outstanding 126305122 | Shares Floating 46004115 |
Shares Outstanding 126305122 | Shares Floating 46004115 | ||
Percent Insiders 33.5 | Percent Institutions 46.03 |
Upturn AI SWOT
Nautilus Biotechnology Inc
Company Overview
History and Background
Nautilus Biotechnology Inc. was founded in 2016 with the goal of revolutionizing proteomics by developing a next-generation single-molecule protein analysis platform. It went public via a SPAC merger in 2021.
Core Business Areas
- Protein Analysis Platform Development: Develops a platform for single-molecule protein analysis, aiming to significantly improve sensitivity, throughput, and cost-effectiveness compared to existing methods.
Leadership and Structure
Suzi Ting is the CEO. The company has a typical structure of a biotechnology company with research and development, operations, and commercial functions. A board of directors governs the company.
Top Products and Market Share
Key Offerings
- Nautilus Proteome Analysis Platform (In Development): Nautilus is developing a platform intended to deliver single-molecule protein analysis for the proteomics market. Competitors include existing proteomics platforms like mass spectrometry (Thermo Fisher Scientific, Agilent) and antibody-based assays (Roche, Danaher). No revenue yet as the product is in development.
Market Dynamics
Industry Overview
The proteomics market is rapidly growing, driven by increasing demand for biomarker discovery, personalized medicine, and drug development. Advancements in technology are driving the growth and competition.
Positioning
Nautilus aims to disrupt the proteomics market with its novel single-molecule analysis platform, offering potentially superior sensitivity and throughput. The company is positioned as an innovator.
Total Addressable Market (TAM)
The total addressable market for proteomics is estimated to be billions of dollars. Nautilus is aiming to capture a significant share by providing high throughput and low-cost alternatives, unlocking new levels of proteomic analysis.
Upturn SWOT Analysis
Strengths
- Novel single-molecule protein analysis technology
- Strong intellectual property position
- Experienced leadership team
- Potential to disrupt a large market
Weaknesses
- Technology is still in development phase
- No revenue generation yet
- High cash burn rate
- Significant execution risk
Opportunities
- Partnerships with pharmaceutical and diagnostic companies
- Expansion into new applications of proteomics
- Potential for acquisitions of complementary technologies
- Increased adoption of proteomics in clinical research
Threats
- Competition from established proteomics companies
- Technological challenges in platform development
- Regulatory hurdles for new diagnostic products
- Economic downturn impacting research funding
Competitors and Market Share
Key Competitors
- TMO
- DHR
- AGIL
Competitive Landscape
Nautilus faces intense competition from established companies with significant resources and existing customer relationships. Nautilus differentiates itself with its novel technology.
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth as the company is pre-revenue.
Future Projections: Future growth is dependent on the successful commercialization of its proteomic platform. Analyst estimates vary but project significant revenue growth in the next 3-5 years upon launch.
Recent Initiatives: Focusing on optimizing the platform performance, expanding capabilities, and building partnerships.
Summary
Nautilus Biotechnology is a pre-revenue company with a promising technology platform but significant execution risk. Successful platform development and commercialization are critical for its future. The company needs to manage its cash burn carefully and secure partnerships. The single molecular protein analysis is a significant innovation and could be a strong player.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor presentations, Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nautilus Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-06-10 | Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 124 | Website https://www.nautilus.bio |
Full time employees 124 | Website https://www.nautilus.bio | ||
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.